Dr. Rai on the Treatment Paradigm for CLL

Kanti R. Rai, MD
Published: Wednesday, Jun 07, 2017



Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses the change in the treatment paradigm for chronic lymphocytic leukemia (CLL).

According to Rai, the treatment paradigm is changing, contrary to the enthusiasm and excitement when new drugs were approved years ago. These treatments are effective but are not cures.

There is a learning curve as to how to best use these new drugs and whether they can be combined to have an additive and synergistic benefit for the patient, explains Rai.
 


Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses the change in the treatment paradigm for chronic lymphocytic leukemia (CLL).

According to Rai, the treatment paradigm is changing, contrary to the enthusiasm and excitement when new drugs were approved years ago. These treatments are effective but are not cures.

There is a learning curve as to how to best use these new drugs and whether they can be combined to have an additive and synergistic benefit for the patient, explains Rai.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x